Indian Vaccination Program for Kids | Aloha Kids Clinic

menu trigger menu trigger

+91 9606077401

Book Appointment

The BCG vaccine helps prevent serious TB (tuberculosis) in kids. It’s made from weak TB germs and is usually given to babies on their left upper arm soon after they are born, often before they leave the hospital. If a baby doesn’t get it right after birth, they can still have it up to the age of 5.

The Hepatitis B vaccine is a highly effective preventive measure against Hepatitis B, a viral infection that can lead to serious liver conditions, including chronic liver disease and liver cancer. It is generally considered safe, with only mild side effects such as soreness at the injection site or a low-grade fever.

The Polio vaccine, available as both Inactivated Polio Vaccine (IPV) and Oral Polio Vaccine (OPV), is crucial for preventing polio, a highly infectious viral disease that can cause paralysis in children. The IPV is administered via injection and the OPV orally, with multiple doses recommended starting shortly after birth and continuing into early childhood. These vaccines are considered very safe and are essential for maintaining polio eradication.

The DTaP (Diphtheria, Tetanus, and acellular Pertussis) vaccine or DTwP (Diphtheria, Tetanus, and whole-cell Pertussis) are similar vaccines are crucial immunization for children, protecting against three serious bacterial infections: diphtheria, tetanus, and pertussis (whooping cough). It’s typically administered in a series of five doses, starting in infancy and continuing through early childhood, with booster shots recommended later in life. The vaccine is highly effective and generally well-tolerated

The Haemophilus influenzae type b (Hib) vaccine is specifically designed to protect against infections caused by the Hib bacterium, which can lead to serious illnesses like meningitis, pneumonia, and epiglottitis, particularly in young children. The vaccine is usually administered in a series of three to four doses, beginning in infancy and continuing through the first year of life. It is highly effective in preventing Hib-related diseases and is generally well-tolerated.

The second dose of the Hepatitis B vaccine is a key component in the immunization series against Hepatitis B, a viral infection that can lead to chronic liver disease and liver cancer. This dose is typically administered when the infant is 6 weeks old. The vaccine is known for its efficacy in providing long-term protection against Hepatitis B and is generally well-tolerated. Common side effects are minimal, usually including soreness at the injection site or mild fever. Completing the full vaccination series is crucial for ensuring effective protection against this serious liver infection.

The Inactivated Polio Vaccine (IPV) is a crucial immunization against poliomyelitis, a disease caused by the poliovirus that can lead to paralysis and even death. IPV, given by injection, contains inactivated (killed) virus, making it very safe and effective. The vaccine is typically administered in multiple doses, starting in infancy and often as part of combination vaccines, and is instrumental in maintaining the global eradication of polio.

The Rotavirus vaccine protects against rotavirus infections, which are a leading cause of severe diarrhea and dehydration in infants and young children worldwide. It is administered orally in two or three doses, depending on the vaccine brand, typically starting at two months of age. The vaccine is highly effective in preventing severe rotavirus infections and related hospitalizations, and is generally well-tolerated with minimal side effects, primarily being mild, temporary gastrointestinal symptoms.

The Pneumococcal Conjugate Vaccine (PCV) is designed to protect against pneumococcal infections caused by the bacterium Streptococcus pneumoniae, which can lead to serious illnesses like pneumonia, meningitis, and sepsis, especially in young children. The vaccine is administered in a series of doses, usually beginning in infancy and continuing through the first couple of years of life. PCV is highly effective in preventing serious pneumococcal diseases and is generally well-tolerated, with common side effects being mild and temporary, such as pain at the injection site, fever, or irritability.

The DTaP (Diphtheria, Tetanus, and acellular Pertussis) and DTwP (Diphtheria, Tetanus, and whole-cell Pertussis) vaccines are critical for protecting against diphtheria, tetanus, and pertussis (whooping cough). The second dose of these vaccines is typically administered at 10 Weeks of age. DTaP contains acellular pertussis components and is known for fewer side effects, while DTwP contains whole-cell pertussis and is more likely to cause mild reactions like fever and swelling at the injection site. Both vaccines are effective in preventing these serious bacterial infections and are essential components of childhood immunization schedules.

The second dose of the Inactivated Polio Vaccine (IPV) is a crucial part of the immunization schedule against poliomyelitis, a disabling and potentially deadly viral disease. This dose is typically administered at 10 Weeks of age. IPV, which contains inactivated (killed) poliovirus, is given via injection and is known for its safety and effectiveness in providing immunity against polio. The vaccine is well-tolerated, with minimal side effects, usually limited to soreness at the injection site. The IPV is essential in maintaining the global eradication efforts of polio.

The second dose of the Haemophilus influenzae type b (Hib) vaccine is an essential part of the immunization schedule to protect against infections caused by the Hib bacterium. This includes serious illnesses like meningitis, pneumonia, and epiglottitis. Typically administered at 4 months of age, this dose is crucial for building adequate immunity in young children. The Hib vaccine is highly effective and generally well-tolerated, with side effects usually being mild and transient, such as pain or swelling at the injection site or a low-grade fever. This vaccine plays a significant role in preventing serious Hib-related diseases.

The third dose of the Hepatitis B vaccine is an essential step in the vaccination series to ensure comprehensive protection against Hepatitis B, a virus that can cause chronic liver problems, including liver cancer. This dose is typically given at 10 weeks of age, completing the primary vaccination series. The Hepatitis B vaccine is highly effective in preventing Hepatitis B infection and is generally safe, with common side effects being mild and limited to soreness at the injection site or a low-grade fever. This final dose in the series is crucial for long-term immunity against Hepatitis B.

The second dose of the Rotavirus vaccine is a crucial part of the immunization schedule to protect against rotavirus infections, which are a leading cause of severe diarrhea and dehydration in infants and young children. This dose is usually administered at 10 Weeks of age. The vaccine is given orally and is highly effective in preventing severe rotavirus gastroenteritis. It is generally well-tolerated, with the most common side effects being mild, temporary gastrointestinal symptoms like diarrhea or vomiting. Completing the rotavirus vaccination series is important for effective protection against this common and potentially serious virus.

The second dose of the Pneumococcal Conjugate Vaccine (PCV) is an integral part of the vaccination regimen to protect against infections caused by Streptococcus pneumoniae. These infections can lead to serious illnesses such as pneumonia, meningitis, and sepsis, especially in young children. Typically administered at 10 Weeks of age, this dose is crucial for building and strengthening immunity against pneumococcal diseases. The PCV is highly effective and generally well-tolerated, with common side effects being mild, such as pain or swelling at the injection site or a low-grade fever. This second dose is key to ensuring sustained protection against pneumococcal infections.

The third dose of the DTaP (Diphtheria, Tetanus, and acellular Pertussis) or DTwP (Diphtheria, Tetanus, and whole-cell Pertussis) vaccine is a key part of the childhood immunization schedule. Administered typically at 14 Weeks of age, this dose further enhances protection against diphtheria, tetanus, and pertussis (whooping cough). The DTaP vaccine, with acellular pertussis components, is known for fewer side effects, while DTwP, containing the whole-cell pertussis component, can cause more noticeable reactions like fever and swelling at the injection site. Both forms are highly effective in preventing these serious bacterial infections, making this third dose essential for sustained immunity.

The third dose of the Inactivated Polio Vaccine (IPV) is a crucial element in the immunization series against poliomyelitis, a disease that can lead to paralysis and is caused by the poliovirus. This dose is usually administered at 14 Weeks of age. IPV, containing inactivated (killed) poliovirus and given via injection, is safe and effective in providing immunity against polio. It is well-tolerated, with minimal side effects, often limited to soreness at the injection site. This third dose is vital for ensuring comprehensive and long-lasting protection against polio.

The third dose of the Haemophilus influenzae type b (Hib) vaccine is a critical part of the immunization schedule, offering continued protection against serious infections caused by the Hib bacterium, such as meningitis, pneumonia, and epiglottitis. Typically given at 14 Weeks of age, this dose is essential for reinforcing the child’s immunity against these potentially life-threatening diseases. The Hib vaccine is highly effective and generally well-tolerated, with common side effects being mild, including temporary soreness at the injection site or a low-grade fever. Completing this third dose is vital for the robust prevention of Hib-related illnesses.

The third dose of the Rotavirus vaccine is an important component in the immunization series against rotavirus, a leading cause of severe diarrhea in young children. Administered typically at 14 Weeks of age, this dose completes the rotavirus vaccination schedule. The vaccine, given orally, is highly effective in preventing severe rotavirus infections and related complications. It is generally well-tolerated, with mild and temporary side effects such as mild gastrointestinal discomfort or irritability. This final dose is crucial in ensuring comprehensive protection against rotavirus.

The third dose of the Pneumococcal Conjugate Vaccine (PCV) is a critical component in the vaccination series against infections caused by the bacterium Streptococcus pneumoniae. This dose, usually given at 14 Weeks of age, further strengthens immunity against serious illnesses such as pneumonia, meningitis, and sepsis, particularly in infants and young children. The PCV is known for its effectiveness and safety, with typical side effects being mild and including localized pain or swelling at the injection site, and occasionally, a low-grade fever. Completing this third dose is essential for ensuring robust and lasting protection against various pneumococcal diseases.

The Inactivated Influenza Vaccine (IIV), commonly known as the flu shot, is formulated to protect against seasonal influenza, a respiratory virus that can cause serious illness. It contains killed influenza virus strains, selected annually based on predictions for the most prevalent strains. Administered via injection, it’s recommended yearly for everyone over six months of age. The IIV is generally safe and well-tolerated, with common side effects including soreness at the injection site, mild fever, and muscle aches, typically lasting a short period.

The Typhoid Conjugate Vaccine (TCV) is specifically designed to provide immunity against typhoid fever, a serious bacterial infection caused by Salmonella Typhi. This vaccine offers longer-lasting protection than older typhoid vaccines and is suitable for children over six months of age. Administered as a single dose injection, TCV is highly effective in preventing typhoid fever and is generally well-tolerated. Common side effects are mild and may include pain at the injection site, fever, and headache, usually resolving within a few days.

This is the second dose and is given after 4 weeks from receiving the first dose. The Inactivated Influenza Vaccine (IIV), commonly known as the flu shot, is formulated to protect against seasonal influenza, a respiratory virus that can cause serious illness. It contains killed influenza virus strains, selected annually based on predictions for the most prevalent strains. Administered via injection, it’s recommended yearly for everyone over six months of age. The IIV is generally safe and well-tolerated, with common side effects including soreness at the injection site, mild fever, and muscle aches, typically lasting a short period.

The Measles, Mumps, and Rubella (MMR) vaccine, as per the Indian Academy of Pediatrics (IAP) guidelines, is a critical vaccine for children, providing protection against measles, mumps, and rubella. The IAP recommends the first dose of MMR at 9 months of age, followed by a second dose at 15 months. This schedule may vary slightly based on regional policies and specific healthcare settings. The MMR vaccine is highly effective and safe, with common side effects being mild, including fever, mild rash, and swelling at the injection site. This vaccination is essential for preventing these potentially serious viral diseases.

The Hepatitis A vaccine provides effective protection against Hepatitis A, a liver infection caused by the Hepatitis A virus. Typically administered in two doses, the first dose is given at the age of one year, followed by a second dose 6 months later. This vaccine is known for its high efficacy and long-term immunity against Hepatitis A. It is generally well-tolerated, with mild side effects such as soreness at the injection site or mild fever. The widespread use of the Hepatitis A vaccine has significantly reduced the incidence of this disease.

The Japanese Encephalitis (JE) vaccine is designed to protect against Japanese Encephalitis, a mosquito-borne viral infection that primarily affects the brain. The vaccine is particularly recommended for individuals in JE-endemic areas or for travelers to such regions. It’s typically administered in a two-dose schedule, with the doses spaced 28 days apart. The JE vaccine is highly effective in preventing Japanese Encephalitis and is generally well-tolerated, with side effects usually being mild and temporary, such as soreness at the injection site or mild fever. Its use is crucial in mitigating the risk of this potentially severe disease.

The second dose of the Japanese Encephalitis (JE) vaccine is a vital component in the vaccination series against JE, a serious mosquito-borne viral infection that primarily affects the brain. This dose, typically administered 28 days after the first, is crucial for completing the initial immunization process and ensuring enhanced and sustained immunity against the disease. The JE vaccine is known for its effectiveness and is generally well-tolerated. Side effects, if any, are usually mild and may include soreness at the injection site or a low-grade fever. This second dose is essential, especially in regions where JE is prevalent or for individuals traveling to such areas.

The second dose of the Measles, Mumps, and Rubella (MMR) vaccine is a crucial follow-up in the vaccination schedule, typically administered between 4 to 6 years of age. This dose ensures reinforced immunity against measles, mumps, and rubella, three highly contagious viral diseases. The MMR vaccine is highly effective and safe, with side effects generally being mild and transient, such as a low-grade fever or mild rash. Completing this second dose is essential for long-term protection and plays a significant role in maintaining the control and prevention of these diseases.

The first dose of the Varicella vaccine, aimed at protecting against chickenpox, a highly contagious viral illness, is an important part of the childhood immunization schedule. Typically administered to children at 15 months of age, this vaccine is highly effective in preventing chickenpox and reducing the severity of the illness if contracted. The Varicella vaccine is generally safe and well-tolerated, with common side effects being mild, such as soreness at the injection site, a low-grade fever, or a mild rash. This first dose is crucial for establishing initial immunity against the varicella-zoster virus.

The Pneumococcal Conjugate Vaccine (PCV) booster dose is an important part of the vaccination schedule, aimed at enhancing and prolonging protection against infections caused by the Streptococcus pneumoniae bacteria, including pneumonia, meningitis, and sepsis. This booster is typically administered between 12-15 months of age, following the initial series of PCV doses given in infancy. The booster dose ensures sustained immunity against pneumococcal diseases during early childhood. The PCV is highly effective and well-tolerated, with common side effects being mild, such as localized pain or swelling at the injection site or a slight fever. The booster dose plays a vital role in maintaining long-term protection against various serious pneumococcal infections.

The fourth dose of the DTaP (Diphtheria, Tetanus, and acellular Pertussis) or DTwP (Diphtheria, Tetanus, and whole-cell Pertussis) vaccine, often referred to as the first booster, is a critical part of the childhood immunization series. Typically administered between 16-18 months of age, this dose boosts immunity against diphtheria, tetanus, and pertussis (whooping cough). The DTaP vaccine, containing acellular components of the pertussis bacterium, is associated with fewer side effects, while DTwP, with the whole-cell pertussis component, may cause more noticeable reactions such as fever or swelling at the injection site. Both vaccines are highly effective in sustaining protection against these potentially serious bacterial diseases, making this booster dose essential.

The fourth dose of the Haemophilus influenzae type b (Hib) vaccine, typically administered as a booster between 16-18 months of age, is a vital component in the complete vaccination series against Hib-related infections. These infections can lead to serious illnesses such as meningitis, pneumonia, and epiglottitis, particularly in young children. This booster dose helps to reinforce and extend the protection gained from the initial Hib vaccination series. The vaccine is highly effective and generally well-tolerated, with mild side effects like soreness at the injection site or a low-grade fever being the most common. This fourth dose plays a critical role in ensuring long-term immunity against Hib diseases.

The fourth dose of the Inactivated Polio Vaccine (IPV), often serving as a booster, is an essential part of the polio vaccination schedule. Typically administered between 16-18 months of age, this dose reinforces the immunity developed from the earlier IPV doses, ensuring continued protection against poliomyelitis, a disease that can cause paralysis and other severe complications. IPV, containing inactivated poliovirus, is safe and effective, with side effects usually limited to mild soreness at the injection site. This booster dose is crucial for maintaining long-term immunity against polio, especially in areas where the virus was previously endemic or where risk of importation exists.

The second dose of the Varicella vaccine, essential for reinforcing protection against chickenpox (varicella), is usually administered to children at 16-18 months of age. This booster dose significantly improves immunity against the varicella-zoster virus, reducing the likelihood of contracting chickenpox and diminishing the severity of the disease if it does occur. The Varicella vaccine is well-tolerated, with common side effects being mild, such as soreness at the injection site, a low-grade fever, or a mild rash. Completing the two-dose series is crucial for effective, long-term protection against chickenpox.

The second dose of the Hepatitis A vaccine is an important step in completing the vaccination series for robust protection against Hepatitis A, a virus that causes liver infection. This dose is typically administered between 6 to 18 months after the first dose, usually around the age of 16-18 months. The two-dose series is highly effective in providing long-term immunity against Hepatitis A. The vaccine is generally well-tolerated, with side effects being minimal and often including mild soreness at the injection site or a low-grade fever. This second dose is crucial for ensuring comprehensive and lasting protection against Hepatitis A.

The fifth dose of the DTaP (Diphtheria, Tetanus, and acellular Pertussis) or DTwP (Diphtheria, Tetanus, and whole-cell Pertussis) vaccine, also known as the second booster, is a critical component of the childhood vaccination schedule. This dose is typically administered to children at 5 Years of age. It serves to further reinforce immunity against diphtheria, tetanus, and pertussis (whooping cough), ensuring continued protection as the child grows. Both vaccines are highly effective in maintaining long-term immunity against these serious bacterial diseases, making this second booster dose essential.

The fifth dose of the Inactivated Polio Vaccine (IPV), also known as the second booster, is a key part of the extended immunization schedule against poliomyelitis. Typically administered to children between 4 to 6 years of age, this dose serves to boost and sustain the immunity acquired from the earlier IPV doses. IPV, which contains inactivated poliovirus and is given via injection, is safe and effective. Side effects are generally minimal, often limited to mild soreness at the injection site. This second booster is crucial for maintaining long-term protection against polio, especially important in areas where polio has been eradicated to prevent its re-emergence.

The Indian Academy of Pediatrics (IAP) recommends two standard doses of the Measles, Mumps, and Rubella (MMR) vaccine: the first dose at 9-12 months of age and the second dose at 15-18 months. A routine third dose of the MMR vaccine is not typically part of the IAP’s standard immunization schedule.

However, in specific circumstances, such as during outbreaks or for children with certain medical conditions, the IAP or healthcare providers might recommend an additional dose for enhanced protection. These recommendations can vary based on the prevalence of the diseases, exposure risks, and the latest health guidelines.

For the most accurate and personalized advice, it’s essential to consult with a healthcare professional who can provide current information and recommendations based on the latest IAP guidelines and individual health needs.

The Tdap (Tetanus, Diphtheria, and Pertussis) vaccine is a booster immunization primarily aimed at preteens, teens, and adults. It provides protection against tetanus (lockjaw), diphtheria, and pertussis (whooping cough). Typically, Tdap is administered once, often during the preteen years (around 10-12 years of age), followed by Td (Tetanus and Diphtheria) booster shots every 10 years. This vaccine is crucial for maintaining immunity from childhood vaccinations into adulthood. It is particularly important for pregnant women to receive Tdap during each pregnancy to protect the newborn from pertussis.

The first dose of the Human Papillomavirus (HPV) vaccine is a key step in protecting against HPV infections, which are linked to several types of cancers, including cervical, anal, and oropharyngeal cancers, as well as genital warts. This vaccine is typically recommended at 10 years of age. It is highly effective in preventing the most dangerous HPV strains. The vaccine is generally safe and well-tolerated

The second dose of the Human Papillomavirus (HPV) vaccine is a crucial continuation of the HPV vaccination series, aimed at providing comprehensive protection against HPV-related diseases, including various cancers and genital warts. This second dose is typically administered 6-12 months after the first dose. The vaccine is highly effective in preventing infections with the most dangerous strains of HPV.

The Influenza (Flu) vaccine is an annual vaccination designed to protect against the most common and virulent strains of the influenza virus for the upcoming flu season. Recommended for everyone aged 6 months and older, it plays a critical role in reducing the incidence of flu-related illnesses, hospitalizations, and complications. The flu vaccine comes in various forms, including injected and nasal spray options, and is reformulated each year to counter the rapidly evolving flu viruses. Common side effects are generally mild and may include soreness at the injection site for the shot, or runny nose and sore throat for the nasal spray. Annual flu vaccination is important for maintaining personal health and public health, especially among children and other high-risk populations.

Meningococcal Vaccine

Japanese Encephalitis (JE) Vaccine

Cholera Vaccine

Yellow Fever Vaccine

CALL +91 96060 77401 to schedule the appointment today

Click Here to Book An Appointment

+91 96060 77401

Aloha Kids Clinic
No 531, 2nd Floor,
Nammalaya Building
Doddakallasandra,
Bangalore – 560062

admin@alohakidsclinic.com

Sign up for the Aloha newsletter to receive all the news offers and discounts from the Aloha Kids clinic.

www.facebook.com/alohakidsclinic

@alohakidsclinic

www.instagram.com/alohakidsclinic_

+91 96060 77401

Aloha Kids Clinic
No 531, 2nd Floor,
Nammalaya Building,
Doddakallasandra,
Bangalore – 560062

admin@alohakidsclinic.com

Sign up for the Aloha newsletter to receive all the news offers and discounts from Aloha Kids clinic.

www.facebook.com/alohakidsclinic

@alohakidsclinic

www.instagram.com/alohakidsclinic_

Copyright by Aloha Kids Clinic,2023. All rights reserved.

Copyright by Aloha kids clinic,2023 All rights reserved.